Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2009 Nov 10;165(12):1039–1044. doi: 10.1016/j.neurol.2009.09.010

Latent viral infections of the nervous system: Role of the host immune response

Infections virales chroniques du système nerveux central : rôle de la réponse immune

M Lafon 1
PMCID: PMC7118798  PMID: 19906390

Abstract

Viruses that infect the nervous system may cause acute, chronic or latent infections. Despite the so-called immunoprivileged status of the nervous system, immunosurveillance plays an important role in the fate of viral infection of the brain. Herpes simplex virus 1 (HSV-1) persists in the nervous system for the life of the host with periodic stress induced reactivation that produces progeny viruses. Prevention of reactivation requires a complex interplay between virus neurons, and immune response. New evidence supports the view that CD8+T cells employing both lytic granule- and IFN-gamma-dependent effectors are essential in setting up and maintaining HSV-1 latency. HSV-1 infection of the nervous system can be seen as a parasitic invasion which leaves the individual at risk for subsequent reactivation and disease. The recent observation that herpes virus latency may confer protection against experimental bacterial infection suggests that unexpected symbiosis may exist between latent viruses and the infected nervous system of its host.

Keywords: Virus, Neuroimmunology, HSV-1, Latency, Neurons, TLR, CD8, IFN-γ, Symbiosis

1. Introduction

Neurotropic viruses cause serious neurological diseases in humans. Development of the disease as an acute or latent infection results of several factors among which the strength of the viral load, the potency of the host immune response and the strategies of virus to escape from the immune response are important factors. In most experimental virus infections of the brain the rapid production of a local innate immune response, including the production of type I interferon (type I IFN) is paramount for host survival (Griffin, 2003). In other instances, the virus burden is so high that clearance of infection by the immune system from the brain fails. This is for example the case of fatal encephalitic cases of West Nile virus encephalitis in mouse model and in humans, where death occurs despite accumulation of inflammatory infiltrates consisting predominantly of nodules of activated microglia, T and B cells, macrophages (Agamanolis et al., 2003, Brehin et al., 2008, Kelley et al., 2003). Failure of the immune response to clear infection off the brain may also result of immunoevasive strategies selected by viruses to evade the host immune response. A well-characterized case is rabies. Rabies virus has developed sophisticated mechanisms to destroy or inactivate ‘protective’ T cells that migrate into the infected nervous system, as a result of the overexpression of immunosubversive molecules such as FasL, HLA-G or B7-H1 in the infected nervous system (Lafon et al., 2006, Lafon et al., 2008, Baloul et al., 2004). For other virus infection such as herpes simplex virus of type 1 (HSV-1) evasion from the immune response can be in some how incomplete. In HSV-1 brain infection, the host immune constraints are sufficient to contribute to latency but they are not strong enough to clear infection. Weakness of the immune response leads episodically to reactivation of the infection. Nevertheless, the immune response in the brain is not always beneficial and can cause immunopathological conditions. An obvious illustration is multiple sclerosis (MS) for which an infectious etiology has been suspected (Dolei and Perron, 2009, Lunemann and Munz, 2009, Perron et al., 2009, Perron et al., 2001, Tai et al., 2009) and where demyelination results both of inflammatory response and B cell activation. This could be also the case of the influenza-associated encephalopathy, where neurological complications of influenza virus infection have been attributed to the inflammatory reactions in the brain rather to the dysfunction of the infected neurons (Okumura et al., 2009).

2. Immune status of the nervous system

2.1. Innate immune response

Nervous parenchyma – as most tissues – has the capacity to sense viral infection. The innate immune response triggered in situ by the entry of pathogen into the brain is characterized by the production of type I IFN (predominantly IFN-β in the brain [Delhaye et al., 2006, Prehaud et al., 2005]), chimiokines and inflammatory cytokines. Beside intrinsic antiviral property, type I IFN also controls the expression of a large number of genes involved in chemo attractive, antiviral and inflammatory responses, which contribute to the host, defence against brain invasion. Microglia, astrocytes and now neurons have been identified as main innate keepers of the brain (Olson and Miller, 2004, Delhaye et al., 2006, Lafon et al., 2006, Yang et al., 2000, Zhou et al., 2009). Cells of the NS, mainly glial cells, express receptors such as Toll-like receptors (TLR) or RIG-like (RLR) which allow them to recognize and respond to the presence of danger signals and Pathogen Associated Molecular Patterns (PAMPS) encoded by pathogens (Furr et al., 2008, Olson and Miller, 2004). Only recently neurons were found to express TLRs and RLRs, (Lafon et al., 2006, Tang et al., 2007, Tang et al., 2008). TLR3 is strongly expressed by Purkinje neurons in the cerebellum of human brains affected by viral encephalitis, amyotrophic lateral sclerosis, stroke or Alzheimer disease (Jackson et al., 2006).

It is still unclear whether the innate immune responses of the brain are as efficient as those in periphery. Injection of the bacterial component LPS into the brain parenchyma elicits neutrophil and monocyte recruitment within 2 h postinjection into the skin, whereas monocyte recruitment is observed only after 2 days when LPS is injected into the brain parenchyma (Andersson et al., 1992). This reduced inflammatory response may result of the property of neurons to reduce inflammation and regulate microglial phenotype during infection or injury (Meuth et al., 2008). Control of local glial inflammation occurs via the expression by neurons of receptors such as CD47, CD22, CD200 and by their ligands on glial cells (Griffiths et al., 2007, Hoek et al., 2000, Wright et al., 2000).

Nevertheless, the type I IFN in the infected nervous system is essential in controlling some neurotropic infections. This is the case for coronavirus clearance off the brain, for which type I IFN response is primordial irrespective of functional adaptive immune response (Ireland et al., 2008). Neuronal expression of TLR3 seems to play a major role in the control of neurotropic viral infection, either decreasing viral replication in the case of West Nile virus infections or more surprisingly by promoting virus neuronal infection as shown in the case of rabies virus (Daffis et al., 2008, Menager et al., 2009). Moreover, a role of TLR3 and the resulting innate immune response has been evoked in the susceptibility of children to encephalitis associated to HSV-1 infection (HSVE). When HSV-1 infects the temporal neurons, it causes severe HSVE, with 60% of fatality in absence of treatment. Origin of the tropism is not yet understood, nevertheless, inefficient innate immune response may play a role since HSVE development has been linked to TLR3 signalling deficiency, either through TLR3 polymorphism (Zhang et al., 2007) or to UNC-93B deficiency (Casrouge et al., 2006). UNC-93B- and TLR3-deficient patients appear to be specifically prone to HSVE, although clinical penetrance is incomplete. Children with predisposition to HSVE carry an heterozygous mutation in TLR3 at the crucial site for dsRNA binding to TLR3 and TLR3 multimerization. UNC93B1 binds the transmembrane domain of TLR3, 7/8 and 9. It is specifically involved in the trafficking of TLR3, 7/8 and 9. In its absence, TLR3, 7/8 and 9 cannot reach anymore the endolysosomes, and signalling is impaired (Brinkmann et al., 2007). Humans with homologous germline mutation show impaired cytokine production upon TLR3, 7/8 and 9 stimulation.

2.2. Adaptive immune response in the brain

If an allograft is implanted into the brain, rejection is delayed compared to grafts in other organs (Medawar, 1991). This phenomenon has given rise to the concept that general rules of the immune system are not applicable to the central nervous system and that the brain – an organ with poor regenerative capacity – enjoys immunological privilege. The ‘immune privilege’ of the central nervous system is a longstanding notion which, over time, has acquired several misconceptions and a lack of precision in its definition (Galea et al., 2007). Different compartments composed the nervous system: parenchyma, ventricles containing the choroid plexus and filled with cerebrospinal fluid CSF and the meninges. The immune privilege is solely applicable to the nervous parenchyma and not to the other tissues such as meninges, choroid plexus, circumventricular organs and ventricles nor to CSF. Experimentally, a virus infection confined to the parenchymal substance of the brain primed the immune system inefficiently or not at all (Byrnes et al., 1996a, Stevenson et al., 1997). In contrast, infection in the CSF elicits a comparable immune response to intranasal infection, with an antiviral proliferative response in the draining lymph nodes (Stevenson et al., 1997). These different situations result on the absence of lymphoid organs into the nervous system and the distinct capacities of antigens to be drained or not from the nervous system towards the cervical lymph nodes (Galea et al., 2007, Weller et al., 2009). Even if immune privilege of nervous parenchyma is well established, it is not a barrier for host defence, since all neurotropic viruses reach the brain after an initial entry in the peripheral tissues, such as muscle, skin or intestinal cells. In these conditions, detection of the pathogen by the peripheral immune system has already occurred and complete immune response has been triggered against the foreign pathogen. The so-called blood brain barrier is not a barrier either for access of T, B and macrophages into the brain from the periphery, since, once activated, immune expressing surface adhesion molecules have the capacity to enter the nervous system (Engelhardt, 2008). In contrast, it is well-documented that after there entry, the migratory immune cells faced unfavourable conditions for survival. This results of a series of parameters controlled by neurons that seriously dampen T cells activity. For example, secretion of several neuropeptides and neurotransmitters by neurons such as vasointestinal peptide, calcitonin gene related peptide, norepinephrin and alpha melanocyte stimulating hormone down regulate the activity of T cells (Niederkorn, 2006). T cells can be subjected to apoptosis by encountering FasL (Baloul et al., 2004). T cells can also be converted into regulatory T cells in presence of TGF-β secreted by neurons (Liu et al., 2006).

Surprisingly despite this rigorous regulation, T cells can still participate to the immunosurveillance against brain infection as illustrated by the side effect attributed to the use of natalizumab. Natalizumab is a humanized recombinant monoclonal antibody that efficiently reduces inflammation of nervous system in MS patients. This mAb targeting the α4 subunit of α4β1 integrin expressed by T cells inhibits alpha (4) integrin-mediated adhesion of human T cells to the inflamed BBB (Bauer et al., 2009, Coisne et al., 2009). Nevertheless, a few MS patients treated with Natalizumab in clinical trials developed a progressive multifocal leukoencephalopathy caused by the polyomavirus JC, an opportunistic viral infection of the NS (Stuve, 2008). This might be related to the property of Natalizumab to decrease the entry into the brain of protective lymphocytes allowing the infection of the nervous system by the JC virus a human neuroropic poyomavirus, a virus requiring strong suppression of the immune system in order to thrive. This opportunity occurs after Natalizmab treatment and as told by Igor Koralnik “Bad things may happen when rescuers are turned back at the gates” (Berger and Koralnik, 2005). This side effect illustrates the critical role of immuneresponse – despite the immunosuppressive neuronal local environement – in protecting the brain against viral infection. Role of immune response in brain protection against invading pathogens, is also illustrated by HIV-infected subjects progressing into symptomatic AIDS and concomitantly their immune response deteriorating, they become vulnerable to opportunistic infections such as Cryptococcus neoformans (2–30% of cases), human cytomegalovirus, HCMV (9%), toxoplasmosis (4%), HSV-1 (4%) as well as Epstein-Barr virus infection (5–10%) the latest causing primary central nervous system lymphoma (Anthony et al., 2008). Indeed T cells, are major actors in the clearance of viral infections (Baloul et al., 2004, Bantug et al., 2008, Byrnes et al., 1996b, Galelli et al., 2000, Lafon et al., 2008). Nevertheless, in some cases, as illustrated below, T cells may have dual role in the fight against infection in the nervous system.

3. Dual role of immune response in HSV-1 latency

HSV-1 establishes a lifelong persistent infection of human peripheral nervous system. During primary infection, virus enters the nervous termini located in mouth-pharyngeal area, and then travels by retrograde axonal transport up to the bodies of the sensory nerves in sensory ganglia. Acute infection is replaced by a latent infection where viral genomes persist without viral particles production. Reactivation from latency can occur sporadically upon different triggering such as UV irradiation or stress. Reactivation results most of the times in benign cold sores and rarely in severe blinding immunopathological herpes stromal keratitis. The role of the immune responses in the control of acute HSV infection, the establishment of the latency and reactivation have been studied in a mouse model of infection, where corneal scarification in presence of virus result in the infection of trigeminal ganglia mimicking human infection.

3.1. Acute infection

In the first 2–3 days after infection, an innate immune response is quickly triggered as soon as the virus starts replication in the ganglia. Both cellular arm of the innate immune response consisting in the triggering of IFN-γ secreting γδ TCR+ T cells or macrophages producing nitric oxide (NO) and tumour necrosis factor alpha (TNF-α) and humoral arm (type 1 IFN, chemokines, cytokines) are rapidly triggered⋅ The recognition of HSV components is both TLRs (2 and 9) and RLRs-dependent(Krug et al., 2004, Kurt-Jones et al., 2004, Lund et al., 2003, Rasmussen et al., 2007, Sorensen et al., 2008). Despite the capacity of HSV-1 to impede the IFN response later in the virus cycle (Randall and Goodbourn, 2008), this early competent innate immune response is sufficient to eliminate most – but not all – replicating virus from the infected ganglia. Plasmacytoid and conventional DCs are also triggered to produce type I IFN which is essential for the activation of CD8+ T cells and expansion of memory population (Garcia-Sastre and Biron, 2006). Indeed memory CD8+ T cells infiltrate the ganglion by day 6 post-infection, expand and settle in the trigeminal ganglion for the rest of life of the infected animals. In this period, CD8+ T cells participate to the clearance of virus.

3.2. Establishment of latency

Six days after corneal infection, latency was established in some sensory neurons which do not produce replicating viruses anymore. Molecular events that switch an acute HSV infection into a latent infection are not completely understood. Latency is characterized by circularization of the viral genome and the expression of latency associated transcripts (LATs) and viral transcripts corresponding to immediate early (α) early (β) and even late (γ1) viral genes (Feldman et al., 2002, Stevens, 1987). It is not excluded that the cell type provides a critical environment for establishment of latency; in the experimental ocular infection of mice, HSV-1 establishes latency preferentially within A5 neurons, a subset of sensory neurons expressing Galβ1-4GlcNAc-R epitopes (Yang et al., 2000). This subset of neurons could correspond to neurons where expression of lytic viral genes such as ICP0 a gene which prevents circularization of viral genome, is impaired (Jackson and DeLuca, 2003, Margolis et al., 1992). Intriguingly enough, establishment of latency may also require CD8+T cells since mice genetically deficient in CD8+T cells or depleted in CD8+T cells failed to establish uniform latency (Gesser et al., 1994, Simmons and Tscharke, 1992). Resident CD8+T cells located in the latently-infected ganglia are specific for the glycoprotein B and since they expressed the marker of activation CD69 they should result of recent viral antigen encountering and activation. Indeed transcripts and viral proteins can be detected in latently-infected mouse neurons (Sawtell, 2003). This observation challenges the concept that HSV-1 latency represents a silent infection that should be ignored by the host immune response and suggests instead the antigen direct retention of memory CD8+T cells (Khanna et al., 2003).

CD8+ T lymphocytes play a critical role in preventing virus reactivation – a phenomenon which can occur in a small number of cells harbouring latent genomes, (1–5%) only, but sufficient enough to cause disease. It has been shown the reactivation is blocked by CD8+ T cells which produced IFN−γ (Khanna et al., 2003). The CD8+ T cells produce IFN-γ which inhibits the expression of the viral gene, ICP0 that prevents genome circularisation (Halford and Schaffer, 2001, Knickelbein et al., 2008, Steed et al., 2006). The IFN-γ receptor is constitutively expressed in many neuronal populations (Robertson et al., 2000, Vikman et al., 1998), nevertheless, not all the neurons expressed receptor for IFN-γ, prevention of reactivation by IFN-γ would be restricted to IFN-γ receptor positive cells only. In neurons lacking IFN-γ receptor, it is thought that some virus-mediated latency mechanisms operate.

The CD8+ T cells also polarize their T cell receptor (TCR) to the junction with neurons forming immunological synapses where the lytic granules of perforine and granzymes accumulated (Knickelbein et al., 2008). The function of lytic granules is not to trigger death of the surrounding HSV-infected neurons. Instead, lytic granules inhibit the expression of ICP4, a viral gene essential for further viral gene expression. Prevention of reactivation is controlled both by lytic granules and by IFN-γ. Thus, it has been proposed that altogether the virus, the neurons and CD8+T cells are complementary actors in maintaining HSV1 latency (Divito et al., 2006).

In addition, HSV latency may confer a surprising benefit to the host. It appears that symbiotic protection could be offered form bacterial infection to the host harbouring HSV infection. Mice latently infected with a murine gamma herpes virus 68, were more resistant to bacterial infections than the non-latently virally infected mice. This effect is mediated by the prolonged production of the antiviral IFN-γ and the resulting systemic activation of macrophages (Barton et al., 2007). Thus, viral latency could be seen as a symbiotic relationship with immune benefit for the host. It remains to be shown whether this symbiotic protection do work in humans too.

4. Conclusion

Neurotropic virus and host immune responses can build intricate and complex interactions controlling viral pathology. Viral infections of the nervous system are powerful models to better understand how the nervous system controls inflammation and invading immune cells. Viral neuroimmunology studies may contribute to a better understanding of the harmful mechanisms leading to neurodegenerative diseases.

References

  1. Agamanolis D.P., Leslie M.J., Caveny E.A., Guarner J., Shieh W.J., Zaki S.R. Neuropathological findings in West Nile virus encephalitis: a case report. Ann Neurol. 2003;54:547–551. doi: 10.1002/ana.10731. [DOI] [PubMed] [Google Scholar]
  2. Andersson P.B., Perry V.H., Gordon S. The acute inflammatory response to lipopolysaccharide in CNS parenchyma differs from that in other body tissues. Neuroscience. 1992;48:169–186. doi: 10.1016/0306-4522(92)90347-5. [DOI] [PubMed] [Google Scholar]
  3. Anthony IC, Simmonds P, Bell JE. HIV infection of the central nervous system. In: Schokes C, editor. Neurotropic Viral Infections. 2008. p. 167–189.
  4. Baloul L., Camelo S., Lafon M. Up-regulation of Fas ligand (FasL) in the central nervous system: a mechanism of immune evasion by rabies virus. J Neurovirol. 2004;10:372–382. doi: 10.1080/13550280490521122. [DOI] [PubMed] [Google Scholar]
  5. Bantug G.R., Cekinovic D., Bradford R., Koontz T., Jonjic S., Britt W.J. CD8+ T lymphocytes control murine cytomegalovirus replication in the central nervous system of newborn animals. J Immunol. 2008;181:2111–2123. doi: 10.4049/jimmunol.181.3.2111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Barton E.S., White D.W., Cathelyn J.S., Brett-McClellan K.A., Engle M., Diamond M.S. Herpesvirus latency confers symbiotic protection from bacterial infection. Nature. 2007;447:326–329. doi: 10.1038/nature05762. [DOI] [PubMed] [Google Scholar]
  7. Bauer M., Brakebusch C., Coisne C., Sixt M., Wekerle H., Engelhardt B. Beta1 integrins differentially control extravasation of inflammatory cell subsets into the CNS during autoimmunity. Proc Natl Acad Sci U S A. 2009;106:1920–1925. doi: 10.1073/pnas.0808909106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Berger J.R., Koralnik I.J. Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences. N Engl J Med. 2005;353:414–416. doi: 10.1056/NEJMe058122. [DOI] [PubMed] [Google Scholar]
  9. Brehin A.C., Mouries J., Frenkiel M.P., Dadaglio G., Despres P., Lafon M. Dynamics of immune cell recruitment during West Nile encephalitis and identification of a new CD19+B220-BST-2+ leukocyte population. J Immunol. 2008;180:6760–6767. doi: 10.4049/jimmunol.180.10.6760. [DOI] [PubMed] [Google Scholar]
  10. Brinkmann M.M., Spooner E., Hoebe K., Beutler B., Ploegh H.L., Kim Y.M. The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling. J Cell Biol. 2007;177:265–275. doi: 10.1083/jcb.200612056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Byrnes A.P., MacLaren R.E., Charlton H.M. Immunological instability of persistent adenovirus vectors in the brain: peripheral exposure to vector leads to renewed inflammation, reduced gene expression, and demyelination. J Neurosci. 1996;16:3045–3055. doi: 10.1523/JNEUROSCI.16-09-03045.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Byrnes A.P., Wood M.J., Charlton H.M. Role of T cells in inflammation caused by adenovirus vectors in the brain. Gene Ther. 1996;3:644–651. [PubMed] [Google Scholar]
  13. Casrouge A., Zhang S.Y., Eidenschenk C., Jouanguy E., Puel A., Yang K. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science. 2006;314:308–312. doi: 10.1126/science.1128346. [DOI] [PubMed] [Google Scholar]
  14. Coisne C., Mao W., Engelhardt B. Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis. J Immunol. 2009;182:5909–5913. doi: 10.4049/jimmunol.0803418. [DOI] [PubMed] [Google Scholar]
  15. Daffis S., Samuel M.A., Suthar M.S., Gale M., Jr., Diamond M.S. Toll-like receptor 3 has a protective role against West Nile virus infection. J Virol. 2008;82:10349–10358. doi: 10.1128/JVI.00935-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Delhaye S., Paul S., Blakqori G., Minet M., Weber F., Staeheli P. Neurons produce type I IFN during viral encephalitis. Proc Natl Acad Sci U S A. 2006;103:7835–7840. doi: 10.1073/pnas.0602460103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Divito S., Cherpes T.L., Hendricks R.L. A triple entente: virus, neurons, and CD8+ T cells maintain HSV-1 latency. Immunol Res. 2006;36:119–126. doi: 10.1385/IR:36:1:119. [DOI] [PubMed] [Google Scholar]
  18. Dolei A., Perron H. The multiple sclerosis-associated retrovirus and its HERV-W endogenous family: a biological interface between virology, genetics, and immunology in human physiology and disease. J Neurovirol. 2009;15:4–13. doi: 10.1080/13550280802448451. [DOI] [PubMed] [Google Scholar]
  19. Engelhardt B. The blood-central nervous system barriers actively control immune cell entry into the central nervous system. Curr Pharm Des. 2008;14:1555–1565. doi: 10.2174/138161208784705432. [DOI] [PubMed] [Google Scholar]
  20. Feldman L.T., Ellison A.R., Voytek C.C., Yang L., Krause P., Margolis T.P. Spontaneous molecular reactivation of herpes simplex virus type 1 latency in mice. Proc Natl Acad Sci U S A. 2002;99:978–983. doi: 10.1073/pnas.022301899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Furr S.R., Chauhan V.S., Sterka D., Jr., Grdzelishvili V., Marriott I. Characterization of retinoic acid-inducible gene-I expression in primary murine glia following exposure to vesicular stomatitis virus. J Neurovirol. 2008:1–11. doi: 10.1080/13550280802337217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Galea I., Bechmann I., Perry V.H. What is immune privilege (not)? Trends Immunol. 2007;28:12–18. doi: 10.1016/j.it.2006.11.004. [DOI] [PubMed] [Google Scholar]
  23. Galelli A., Baloul L., Lafon M. Abortive rabies virus central nervous infection is controlled by T lymphocyte local recruitment and induction of apoptosis. J Neurovirol. 2000;6:359–372. doi: 10.3109/13550280009018300. [DOI] [PubMed] [Google Scholar]
  24. Garcia-Sastre A., Biron C.A. Type 1 IFNs and the virus-host relationship: a lesson in detente. Science. 2006;312:879–882. doi: 10.1126/science.1125676. [DOI] [PubMed] [Google Scholar]
  25. Gesser R.M., Valyi-Nagy T., Fraser N.W. Restricted herpes simplex virus type 1 gene expression within sensory neurons in the absence of functional B and T lymphocytes. Virology. 1994;200:791–795. doi: 10.1006/viro.1994.1243. [DOI] [PubMed] [Google Scholar]
  26. Griffin D.E. Immune responses to RNA-virus infections of the CNS. Nat Rev Immunol. 2003;3:493–502. doi: 10.1038/nri1105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Griffiths M., Neal J.W., Gasque P. Innate immunity and protective neuroinflammation: new emphasis on the role of neuroimmune regulatory proteins. Int Rev Neurobiol. 2007;82:29–55. doi: 10.1016/S0074-7742(07)82002-2. [DOI] [PubMed] [Google Scholar]
  28. Halford W.P., Schaffer P.A. ICP0 is required for efficient reactivation of herpes simplex virus type 1 from neuronal latency. J Virol. 2001;75:3240–3249. doi: 10.1128/JVI.75.7.3240-3249.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Hoek R.M., Ruuls S.R., Murphy C.A., Wright G.J., Goddard R., Zurawski S.M. Down-regulation of the macrophage lineage through interaction with OX2 (CD200) Science. 2000;290:1768–1771. doi: 10.1126/science.290.5497.1768. [DOI] [PubMed] [Google Scholar]
  30. Ireland D.D., Stohlman S.A., Hinton D.R., Atkinson R., Bergmann C.C. Type I IFNs are essential in controlling neurotropic coronavirus infection irrespective of functional CD8 T cells. J Virol. 2008;82:300–310. doi: 10.1128/JVI.01794-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Jackson A.C., Rossiter J.P., Lafon M. Expression of Toll-like receptor 3 in the human cerebellar cortex in rabies, herpes simplex encephalitis, and other neurological diseases. J Neurovirol. 2006;12:229–234. doi: 10.1080/13550280600848399. [DOI] [PubMed] [Google Scholar]
  32. Jackson S.A., DeLuca N.A. Relationship of herpes simplex virus genome configuration to productive and persistent infections. Proc Natl Acad Sci U S A. 2003;100:7871–7876. doi: 10.1073/pnas.1230643100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Kelley T.W., Prayson R.A., Ruiz A.I., Isada C.M., Gordon S.M. The neuropathology of West Nile virus meningoencephalitis. A report of two cases and review of the literature. Am J Clin Pathol. 2003;119:749–753. doi: 10.1309/PU4R-76JJ-MG1F-81RP. [DOI] [PubMed] [Google Scholar]
  34. Khanna K.M., Bonneau R.H., Kinchington P.R., Hendricks R.L. Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity. 2003;18:593–603. doi: 10.1016/s1074-7613(03)00112-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Knickelbein J.E., Khanna K.M., Yee M.B., Baty C.J., Kinchington P.R., Hendricks R.L. Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency. Science. 2008;322:268–271. doi: 10.1126/science.1164164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Krug A., Luker G.D., Barchet W., Leib D.A., Akira S., Colonna M. Herpes simplex virus type 1 activates murine natural IFN-producing cells through toll-like receptor 9. Blood. 2004;103:1433–1437. doi: 10.1182/blood-2003-08-2674. [DOI] [PubMed] [Google Scholar]
  37. Kurt-Jones E.A., Chan M., Zhou S., Wang J., Reed G., Bronson R. Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad Sci U S A. 2004;101:1315–1320. doi: 10.1073/pnas.0308057100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Lafon M., Megret F., Lafage M., Prehaud C. The innate immune facet of brain: human neurons express TLR-3 and sense viral dsRNA. J Mol Neurosci. 2006;29:185–194. doi: 10.1385/JMN:29:3:185. [DOI] [PubMed] [Google Scholar]
  39. Lafon M., Megret F., Meuth S.G., Simon O., Velandia Romero M.L., Lafage M. Detrimental contribution of the immuno-inhibitor B7-H1 to rabies virus encephalitis. J Immunol. 2008;180:7506–7515. doi: 10.4049/jimmunol.180.11.7506. [DOI] [PubMed] [Google Scholar]
  40. Liu Y., Teige I., Birnir B., Issazadeh-Navikas S. Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. Nat Med. 2006;12:518–525. doi: 10.1038/nm1402. [DOI] [PubMed] [Google Scholar]
  41. Lund J., Sato A., Akira S., Medzhitov R., Iwasaki A. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med. 2003;198:513–520. doi: 10.1084/jem.20030162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Lunemann J.D., Munz C. EBV in MS: guilty by association? Trends Immunol. 2009;30:243–248. doi: 10.1016/j.it.2009.03.007. [DOI] [PubMed] [Google Scholar]
  43. Margolis D.M., Rabson A.B., Straus S.E., Ostrove J.M. Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes. Virology. 1992;186:788–791. doi: 10.1016/0042-6822(92)90048-t. [DOI] [PubMed] [Google Scholar]
  44. Medawar P.B. The Nobel Lectures in Immunology. The Nobel Prize for Physiology or Medicine, 1960. Immunological tolerance. Scand J Immunol. 1991;33:337–344. doi: 10.1111/j.1365-3083.1991.tb01779.x. [DOI] [PubMed] [Google Scholar]
  45. Menager P., Roux P., Megret F., Bourgeois J.P., Le Sourd A.M., Danckaert A. Toll-like receptor 3 (TLR3) plays a major role in the formation of rabies virus Negri Bodies. PLoS Pathog. 2009;5:e1000315. doi: 10.1371/journal.ppat.1000315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Meuth S.G., Simon O.J., Grimm A., Melzer N., Herrmann A.M., Spitzer P. CNS inflammation and neuronal degeneration is aggravated by impaired CD200-CD200R-mediated macrophage silencing. J Neuroimmunol. 2008;194:62–69. doi: 10.1016/j.jneuroim.2007.11.013. [DOI] [PubMed] [Google Scholar]
  47. Niederkorn J.Y. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol. 2006;7:354–359. doi: 10.1038/ni1328. [DOI] [PubMed] [Google Scholar]
  48. Okumura A., Abe S., Kidokoro H., Mizuguchi M. Acute necrotizing encephalopathy: a comparison between influenza and non-influenza cases. Microbiol Immunol. 2009;53:277–280. doi: 10.1111/j.1348-0421.2009.00124.x. [DOI] [PubMed] [Google Scholar]
  49. Olson J.K., Miller S.D. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol. 2004;173:3916–3924. doi: 10.4049/jimmunol.173.6.3916. [DOI] [PubMed] [Google Scholar]
  50. Perron H., Bernard C., Bertrand J.B., Lang A.B., Popa I., Sanhadji K. Endogenous retroviral genes. Herpesviruses and gender in Multiple Sclerosis. J Neurol Sci. 2009 doi: 10.1016/j.jns.2009.04.034. [DOI] [PubMed] [Google Scholar]
  51. Perron H., Jouvin-Marche E., Michel M., Ounanian-Paraz A., Camelo S., Dumon A. Multiple sclerosis retrovirus particles and recombinant envelope trigger an abnormal immune response in vitro, by inducing polyclonal Vbeta16 T-lymphocyte activation. Virology. 2001;287:321–332. doi: 10.1006/viro.2001.1045. [DOI] [PubMed] [Google Scholar]
  52. Prehaud C., Megret F., Lafage M., Lafon M. Virus infection switches TLR-3-positive human neurons to become strong producers of beta IFN. J Virol. 2005;79:12893–12904. doi: 10.1128/JVI.79.20.12893-12904.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Randall R.E., Goodbourn S. IFNs and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol. 2008;89:1–47. doi: 10.1099/vir.0.83391-0. [DOI] [PubMed] [Google Scholar]
  54. Rasmussen S.B., Sorensen L.N., Malmgaard L., Ank N., Baines J.D., Chen Z.J. Type I IFN production during herpes simplex virus infection is controlled by cell-type-specific viral recognition through Toll-like receptor 9, the mitochondrial antiviral signaling protein pathway, and novel recognition systems. J Virol. 2007;81:13315–13324. doi: 10.1128/JVI.01167-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Robertson B., Kong G., Peng Z., Bentivoglio M., Kristensson K. IFN-gamma-responsive neuronal sites in the normal rat brain: receptor protein distribution and cell activation revealed by Fos induction. Brain Res Bull. 2000;52:61–74. doi: 10.1016/s0361-9230(00)00240-9. [DOI] [PubMed] [Google Scholar]
  56. Sawtell N.M. Quantitative analysis of herpes simplex virus reactivation in vivo demonstrates that reactivation in the nervous system is not inhibited at early times postinoculation. J Virol. 2003;77:4127–4138. doi: 10.1128/JVI.77.7.4127-4138.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Simmons A., Tscharke D.C. Anti-CD8 impairs clearance of herpes simplex virus from the nervous system: implications for the fate of virally infected neurons. J Exp Med. 1992;175:1337–1344. doi: 10.1084/jem.175.5.1337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Sorensen L.N., Reinert L.S., Malmgaard L., Bartholdy C., Thomsen A.R., Paludan S.R. TLR2 and TLR9 synergistically control herpes simplex virus infection in the brain. J Immunol. 2008;181:8604–8612. doi: 10.4049/jimmunol.181.12.8604. [DOI] [PubMed] [Google Scholar]
  59. Steed A.L., Barton E.S., Tibbetts S.A., Popkin D.L., Lutzke M.L., Rochford R. Gamma IFN blocks gammaherpesvirus reactivation from latency. J Virol. 2006;80:192–200. doi: 10.1128/JVI.80.1.192-200.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Stevens J.G. Defining herpes simplex genes involved in neurovirulence and neuroinvasiveness. Curr Eye Res. 1987;6:63–67. doi: 10.3109/02713688709020070. [DOI] [PubMed] [Google Scholar]
  61. Stevenson P.G., Hawke S., Sloan D.J., Bangham C.R. The immunogenicity of intracerebral virus infection depends on anatomical site. J Virol. 1997;71:145–151. doi: 10.1128/jvi.71.1.145-151.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Stuve O. The effects of natalizumab on the innate and adaptive immune system in the central nervous system. J Neurol Sci. 2008;274:39–41. doi: 10.1016/j.jns.2008.03.022. [DOI] [PubMed] [Google Scholar]
  63. Tai A.K., Luka J., Ablashi D., Huber B.T. HHV-6A infection induces expression of HERV-K18-encoded superantigen. J Clin Virol. 2009 doi: 10.1016/j.jcv.2009.05.019. [DOI] [PubMed] [Google Scholar]
  64. Tang S.C., Arumugam T.V., Xu X., Cheng A., Mughal M.R., Jo D.G. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci U S A. 2007;104:13798–13803. doi: 10.1073/pnas.0702553104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Tang S.C., Lathia J.D., Selvaraj P.K., Jo D.G., Mughal M.R., Cheng A. Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp Neurol. 2008;213:114–121. doi: 10.1016/j.expneurol.2008.05.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Vikman K., Robertson B., Grant G., Liljeborg A., Kristensson K. IFN-gamma receptors are expressed at synapses in the rat superficial dorsal horn and lateral spinal nucleus. J Neurocytol. 1998;27:749–759. doi: 10.1023/a:1006903002044. [DOI] [PubMed] [Google Scholar]
  67. Weller R.O., Djuanda E., Yow H.Y., Carare R.O. Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol. 2009;117:1–14. doi: 10.1007/s00401-008-0457-0. [DOI] [PubMed] [Google Scholar]
  68. Wright G.J., Puklavec M.J., Willis A.C., Hoek R.M., Sedgwick J.D., Brown M.H. Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function. Immunity. 2000;13:233–242. doi: 10.1016/s1074-7613(00)00023-6. [DOI] [PubMed] [Google Scholar]
  69. Yang L., Voytek C.C., Margolis T.P. Immunohistochemical analysis of primary sensory neurons latently infected with herpes simplex virus type 1. J Virol. 2000;74:209–217. doi: 10.1128/jvi.74.1.209-217.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Zhang S.Y., Jouanguy E., Sancho-Shimizu V., von Bernuth H., Yang K., Abel L. Human Toll-like receptor-dependent induction of IFNs in protective immunity to viruses. Immunol Rev. 2007;220:225–236. doi: 10.1111/j.1600-065X.2007.00564.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Zhou L.X., Wang Y.J., Wang Y., Zhou S., Hu L., Ye Activation of toll-like receptor-3 induces IFN-lambda expression in human neuronal cells. Neuroscience. 2009;159:629–637. doi: 10.1016/j.neuroscience.2008.12.036. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Revue Neurologique are provided here courtesy of Elsevier

RESOURCES